TrialLeukemia2019

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

R F Schlenk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.